Cargando…

Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States

Limited data are available on thromboembolic events (TEEs) and mortality in outpatients with coronavirus disease 2019 (COVID-19). This retrospective, observational cohort study identified non-hospitalized COVID-19 outpatients (01/21/2020-01/07/2021) using de-identified Optum(®) COVID-19 Electronic H...

Descripción completa

Detalles Bibliográficos
Autores principales: Peacock, W. Frank, Crawford, James M., Chen, Yen-Wen (Cindy), Ashton, Veronica, Campbell, Alicia K., Milentijevic, Dejan, Spyropoulos, Alex C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421058/
https://www.ncbi.nlm.nih.gov/pubmed/35996822
http://dx.doi.org/10.1177/10760296221120421
_version_ 1784777510735577088
author Peacock, W. Frank
Crawford, James M.
Chen, Yen-Wen (Cindy)
Ashton, Veronica
Campbell, Alicia K.
Milentijevic, Dejan
Spyropoulos, Alex C.
author_facet Peacock, W. Frank
Crawford, James M.
Chen, Yen-Wen (Cindy)
Ashton, Veronica
Campbell, Alicia K.
Milentijevic, Dejan
Spyropoulos, Alex C.
author_sort Peacock, W. Frank
collection PubMed
description Limited data are available on thromboembolic events (TEEs) and mortality in outpatients with coronavirus disease 2019 (COVID-19). This retrospective, observational cohort study identified non-hospitalized COVID-19 outpatients (01/21/2020-01/07/2021) using de-identified Optum(®) COVID-19 Electronic Health Records data. Patient characteristics, occurrence of TEEs, all-cause mortality, and anticoagulant or thrombolytic medication use were evaluated. Of 1,246,067 patients with COVID-19 diagnosis, 141 471 met entry criteria. Mean (standard deviation [SD]) age was 46.1 (17.2) years, 56.8% were female, 72.9% Caucasian, 11.2% African American, and 11.1% Hispanic. Comorbidity burden was low (mean [SD] Quan-Charlson comorbidity index score of 0.43 [1.10]); however, of those with body mass index data, half were obese. During the follow-up period, a TEE occurred in 1.4%, with the proportion of patients with ischemic stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism being similar (approximately 0.4% each). All-cause mortality was 0.7%. Medications included corticosteroids (13.7%), anticoagulants (4.9%), and antiplatelets (2.9%). Overall, in this large cohort analysis, certain demographic and clinical characteristics of patients who experienced TEEs were identified and may help guide management decisions and future clinical trials for COVID-19 outpatients.
format Online
Article
Text
id pubmed-9421058
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-94210582022-08-30 Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States Peacock, W. Frank Crawford, James M. Chen, Yen-Wen (Cindy) Ashton, Veronica Campbell, Alicia K. Milentijevic, Dejan Spyropoulos, Alex C. Clin Appl Thromb Hemost Original Manuscript Limited data are available on thromboembolic events (TEEs) and mortality in outpatients with coronavirus disease 2019 (COVID-19). This retrospective, observational cohort study identified non-hospitalized COVID-19 outpatients (01/21/2020-01/07/2021) using de-identified Optum(®) COVID-19 Electronic Health Records data. Patient characteristics, occurrence of TEEs, all-cause mortality, and anticoagulant or thrombolytic medication use were evaluated. Of 1,246,067 patients with COVID-19 diagnosis, 141 471 met entry criteria. Mean (standard deviation [SD]) age was 46.1 (17.2) years, 56.8% were female, 72.9% Caucasian, 11.2% African American, and 11.1% Hispanic. Comorbidity burden was low (mean [SD] Quan-Charlson comorbidity index score of 0.43 [1.10]); however, of those with body mass index data, half were obese. During the follow-up period, a TEE occurred in 1.4%, with the proportion of patients with ischemic stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism being similar (approximately 0.4% each). All-cause mortality was 0.7%. Medications included corticosteroids (13.7%), anticoagulants (4.9%), and antiplatelets (2.9%). Overall, in this large cohort analysis, certain demographic and clinical characteristics of patients who experienced TEEs were identified and may help guide management decisions and future clinical trials for COVID-19 outpatients. SAGE Publications 2022-08-22 /pmc/articles/PMC9421058/ /pubmed/35996822 http://dx.doi.org/10.1177/10760296221120421 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Manuscript
Peacock, W. Frank
Crawford, James M.
Chen, Yen-Wen (Cindy)
Ashton, Veronica
Campbell, Alicia K.
Milentijevic, Dejan
Spyropoulos, Alex C.
Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States
title Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States
title_full Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States
title_fullStr Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States
title_full_unstemmed Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States
title_short Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States
title_sort real-world analysis of thromboembolic events and mortality of covid-19 outpatients in the united states
topic Original Manuscript
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421058/
https://www.ncbi.nlm.nih.gov/pubmed/35996822
http://dx.doi.org/10.1177/10760296221120421
work_keys_str_mv AT peacockwfrank realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates
AT crawfordjamesm realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates
AT chenyenwencindy realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates
AT ashtonveronica realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates
AT campbellaliciak realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates
AT milentijevicdejan realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates
AT spyropoulosalexc realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates